HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $90.
June 11, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Arrowhead Pharma and maintained a price target of $90, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target of $90 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Arrowhead Pharma, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100